FEMARA Drug Patent Profile

When do Femara patents expire, and when can generic versions of Femara launch?

Femara is a drug marketed by Novartis Pharms and is included in one NDA.

The generic ingredient in FEMARA is letrozole. There are twenty-four drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the letrozole profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Femara

A generic version of FEMARA was approved as letrozole by ACCORD HLTHCARE on June 3^rd, 2011.

Summary for FEMARA

US Patents:	0
Applicants:	1
NDAs:	1

Paragraph IV (Patent) Challenges for FEMARA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
FEMARA	Tablets	letrozole	2.5 mg	020726	1	2006-03-02

US Patents and Regulatory Information for FEMARA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis Pharms	FEMARA	letrozole	TABLET;ORAL	020726-001	Jul 25, 1997	AB	RX	Yes	Yes

International Patents for FEMARA

See the table below for patents covering FEMARA around the world.

Country	Patent Number	Title	Estimated Expiration
Poland	151490
Germany	19775016
Denmark	172190

Supplementary Protection Certificates for FEMARA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0236940	C970011	Netherlands		PRODUCT NAME: LETROZOLUM, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAAR DBAAR ZOUT; NAT. REGISTRATION: RVG 20755 19970106; FIRST REGISTRATION: FR NL 21 881 19960724
0236940	SPC/GB97/013	United Kingdom		PRODUCT NAME: LETROZOLE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: FR 341 474-2 19960724; FR 341 475-9 19960724; UK PL00001/0224 19961118
0236940	97C0053	Belgium		PRODUCT NAME: LETROZOLE; NAT. REGISTRATION NO/DATE: 206 IS 241 F 3 19970616; FIRST REGISTRATION: FR 341 474.2 1996072

FEMARA Market Analysis and Financial Projection

Last updated: February 3, 2026

What Is the Investment Scenario for FEMARA?

FEMARA (letrozole) is an aromatase inhibitor primarily used in hormone receptor-positive breast cancer treatment. Marketed by Novartis, it holds a significant position in the breast cancer therapy segment. Current valuation and growth prospects hinge on patent status, competitive landscape, and emerging indications.

Market Position & Sales Trajectory

• Sales: In 2022, FEMARA generated approximately $490 million globally. Sales have plateaued in developed markets due to patent expiry but remain stable owing to its established position.
• Patent Status: Patent expiration occurred in major markets by 2022, opening the potential for generic competition. However, some formulations and indications may enjoy data exclusivity or regulatory barriers.
• Market Penetration: FEMARA remains the preferred aromatase inhibitor in certain niches, especially in adjuvant breast cancer therapy for postmenopausal women.

Competitive Landscape

• Generic Entry: Expected to pressure prices and market share. Competitors include AstraZeneca’s Faslodex (fulvestrant), Pfizer’s aromatase inhibitors, and generics from multiple manufacturers.
• New Indications: Investigations into neoadjuvant therapy, ovarian stimulation, and breast cancer prevention could extend its commercial lifespan.
• Pricing: Developed markets show pricing pressure post-patent expiry, but emerging markets offer growth potential with lower price points.

Growth Drivers & Risks

• Drivers: Expanding use in early-stage breast cancer, growing breast cancer prevalence in aging populations, and increasing acceptance of hormone-based therapies.
• Risks: Patent cliffs, competition from newer agents with improved efficacy or safety, regulatory hurdles in emerging indications, and reimbursement challenges.

What Are the Fundamentals of FEMARA as an Investment?

Revenue and Profitability

• Revenue Trend: Peaked around $900 million globally in 2012; declined with patent expiry and generic entry but stabilized around $490 million in 2022.
• Margins: Gross margins near 80% pre-generic, declining to approximately 60-65% post-generic. Operating margins reflect R&D and marketing expenses.

R&D and Pipeline Status

• Current R&D Focus: Novartis invested heavily in expanding indications, including breast cancer prevention and ovarian stimulation.
• Pipeline: Few late-stage pipeline assets are directly related; development efforts shift toward combination therapies and biomarker-driven approaches.

Regulatory Environment

• Regulatory Approvals: FEMARA approved by FDA, EMA, and other agencies since 1997.
• Patent Litigation & Exclusivity: Patent challenges from generics began in 2022. Data exclusivity provisions and regulatory barriers may offer interim protections in some regions.

Financial Metrics

Metric	2022	2021	2020
Revenue	$490 million	$510 million	$550 million
Gross Margin	~60-65%	~65-70%	~70%
Operating Margin	~20-25%	~25-30%	~30%
R&D Expenditure	~$50 million	~$45 million	~$40 million

Valuation & Investment Considerations

• Valuation: Due to patent expiry, FEMARA trades at a lower valuation multiple compared to branded specialty drugs. Market capitalization estimates approximate $3 billion.
• Future Outlook: Stabilized revenues with reduced margins; limited growth prospects unless new indications achieve regulatory approval or generics are delayed.

What Are the Key Takeaways?

1. FEMARA is an established breast cancer therapy with a mature market position.
2. Patent expiry has led to significant revenue decline, with generics eroding profitability.
3. The drug's future depends on its adoption in new indications, regulatory approval in emerging markets, and potential delays in generic entry.
4. Competitive pressure from newer agents and biosimilars remains a critical risk.
5. Valuation reflects reduced growth prospects but stable cash flows from existing markets.

What Are Common FAQs About FEMARA?

1. How soon will FEMARA face generic competition?
Generic versions started entering some markets in 2022, with broader penetration expected over the next 1-2 years, depending on regional patent litigations and regulatory processes.

2. Are there new indications that could extend FEMARA’s market?
Yes. Research into breast cancer prevention, neoadjuvant therapy, and ovarian stimulation could provide new revenue streams if approved.

3. How does FEMARA compare with other aromatase inhibitors?
FEMARA was among the first aromatase inhibitors and has an established safety profile. Competitors like AstraZeneca's Faslodex focus on different mechanisms (fulvestrant). Newer agents may offer improved efficacy or safety.

4. What are the key risks for investors?
Patent expiry leading to generic erosion, stiff price competition, regulatory delays in new indications, and potential shifts in treatment guidelines towards alternatives.

5. What is FEMARA’s long-term outlook?
Limited growth potential post-patent expiry unless new approved uses emerge or market dynamics change with delayed generic entry and expanded indications.

---

Citations:

[1] Novartis. FEMARA Product Data. (2022)
[2] Evaluate Pharma. Breast Cancer Drug Market Reports. (2022)
[3] U.S. Patent and Trademark Office. Patent Expiry Announcements. (2022)
[4] IMS Health. Global Oncology Market Trends. (2022)